FETZIMA® (lenomilnacipran) extended-release capsules

LENGTH OF AUTHORIZATION: Up to one year

INITIAL REVIEW CRITERIA (ALL OF THE FOLLOWING MUST BE TRUE):  
- Patient must be ≥18 years old  
- Patient must have a confirmed diagnosis of depression  
- Trial and failure with a minimum of two other antidepressant drugs within the past 365 days.  
  - One of these two antidepressants must have been in the SNRI class AND  
  - Claims history documents a minimum of at least 2 consecutive fills (60 day trial) of the SNRI.  
  (Failure can be defined as inefficacy or intolerability, not non-compliance)

CONTINUATION OF THERAPY:  
- Must have recent claims history (within previous 3 months) of Fetzima

DOSSING & ADMINISTRATION:  
- Recommended dose: 40 mg to 120 mg once daily with or without food.  
- Initiate dose at 20 mg once daily for 2 days and then increase to 40 mg once daily.  
- Based on efficacy and tolerability, increase dose in increments of 40 mg at intervals of 2 or more days.  
- The maximum recommended dose is 120 mg once daily  
- Dosage Form: 20 mg, 40 mg, 80 mg and 120 mg extended release capsules